Completed PHASE3 INTERVENTIONAL 3-arm NCT01499368

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients

A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Koran Erosive Esophagitis Patients

Sponsor: Boryung Pharmaceutical Co., Ltd

Conditions Erosive Esophagitis

Interventions Famotidine Lafutidine Omeprazole

Updated 7 times since 2017 Last updated: Jan 6, 2025 Started: Nov 30, 2011 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Erosive Esophagitis, this trial is completed. The trial is conducted by Boryung Pharmaceutical Co., Ltd and has accumulated 7 data snapshots since 2011. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Feb 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Feb 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Oct 2020 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Oct 2020 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Nov 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Boryung Pharmaceutical Co., Ltd

Data source: Boryung Pharmaceutical Co., Ltd

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.